News Focus
News Focus
Followers 48
Posts 23463
Boards Moderated 0
Alias Born 09/16/2012

Re: learningcurve2020 post# 806562

Wednesday, 01/07/2026 12:47:47 PM

Wednesday, January 07, 2026 12:47:47 PM

Post# of 817888
Hey GoodGuyBill, that IT agreement I posted for you as an example of a proper transparent arrangement now comes with this PR too. Have you ever seen similar copy in a PR coming from NWBO about UCLA?

>>Marker Therapeutics, Inc. (Nasdaq: MRKR) is a clinical-stage immuno-oncology Company with the worldwide exclusive license of Multi-Antigen Targeted T cells (also referred to as Multi-Antigen Recognizing T cells, or MAR-T cells, by Marker), a technology developed at Baylor College of Medicine for the treatment of hematologic and solid tumors. A research team from Baylor College of Medicine has now published groundbreaking work in Nature Medicine investigating Multi-Antigen Targeted T cells in patients with pancreatic cancer.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent NWBO News